Compare Stocks: CYPH, ALXO, WHWK, and ACIU

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.49 -3.1%	$2.38	$2.03 ▼ $4.00	$261.56M	1.59	220,769 shs	132,843 shs
ALXO ALX Oncology	$1.96 +1.0%	$1.91	$0.62 ▼ $2.66	$268.26M	0.42	1.07 million shs	584,061 shs
CYPH Cypherpunk Technologies	$0.64 -0.6%	$0.68	$0.25 ▼ $3.70	$69.83M	0.09	1.29 million shs	561,961 shs
WHWK Whitehawk Therapeutics	$4.46 -4.7%	$4.14	$1.57 ▼ $5.49	$266.80M	0.76	462,817 shs	260,299 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	-3.11%	+5.51%	+5.51%	-10.75%	+13.18%
ALXO ALX Oncology	+1.03%	-6.67%	-3.45%	-3.45%	+196.70%
CYPH Cypherpunk Technologies	-0.62%	-6.48%	-14.42%	-40.65%	+89.97%
WHWK Whitehawk Therapeutics	-4.70%	-6.30%	+15.84%	-5.11%	+160.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.49 -3.1%	$2.38	$2.03 ▼ $4.00	$261.56M	1.59	220,769 shs	132,843 shs
ALXO ALX Oncology	$1.96 +1.0%	$1.91	$0.62 ▼ $2.66	$268.26M	0.42	1.07 million shs	584,061 shs
CYPH Cypherpunk Technologies	$0.64 -0.6%	$0.68	$0.25 ▼ $3.70	$69.83M	0.09	1.29 million shs	561,961 shs
WHWK Whitehawk Therapeutics	$4.46 -4.7%	$4.14	$1.57 ▼ $5.49	$266.80M	0.76	462,817 shs	260,299 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	-3.11%	+5.51%	+5.51%	-10.75%	+13.18%
ALXO ALX Oncology	+1.03%	-6.67%	-3.45%	-3.45%	+196.70%
CYPH Cypherpunk Technologies	-0.62%	-6.48%	-14.42%	-40.65%	+89.97%
WHWK Whitehawk Therapeutics	-4.70%	-6.30%	+15.84%	-5.11%	+160.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	2.40	Hold	$7.50	201.20% Upside
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	134.69% Upside
CYPH Cypherpunk Technologies	2.50	Moderate Buy	$0.90	39.75% Upside
WHWK Whitehawk Therapeutics	2.63	Moderate Buy	$8.20	83.86% Upside

Current Analyst Ratings Breakdown

Latest CYPH, ALXO, WHWK, and ACIU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	ACIU AC Immune	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	ACIU AC Immune	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/31/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/13/2026	WHWK Whitehawk Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
7/10/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/3/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/1/2026	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/1/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$0.90
7/1/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$0.90
6/26/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$4.31M	58.80	N/A	N/A	$0.44 per share	5.66
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.98 per share	N/A
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	$1.29 per share	N/A
WHWK Whitehawk Therapeutics	$7.14M	35.61	N/A	N/A	$3.21 per share	1.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$85.03M	-$0.54	N/A	14.65	N/A	-245.32%	-100.17%	-28.36%	11/3/2026 (Estimated)
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	N/A
CYPH Cypherpunk Technologies	$4.82M	$0.56	1.15	N/A	N/A	N/A	-20.76%	-19.48%	N/A
WHWK Whitehawk Therapeutics	-$20.60M	-$1.12	N/A	N/A	N/A	N/A	-53.89%	-49.97%	N/A

Latest CYPH, ALXO, WHWK, and ACIU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	CYPH Cypherpunk Technologies	N/A	$0.18	N/A	$0.18	N/A	N/A
8/6/2026	Q2 2026	ACIU AC Immune	-$0.1044	$0.03	+$0.1344	$0.03	$9.59 million	$18.67 million
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A
8/6/2026	Q2 2026	WHWK Whitehawk Therapeutics	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	0.11	0.93	1.02
ALXO ALX Oncology	0.07	9.71	9.71
CYPH Cypherpunk Technologies	N/A	79.19	27.28
WHWK Whitehawk Therapeutics	N/A	17.38	11.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
ALXO ALX Oncology	97.97%
CYPH Cypherpunk Technologies	30.46%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
ALXO ALX Oncology	12.40%
CYPH Cypherpunk Technologies	3.50%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	101.77 million	97.09 million	Optionable
ALXO ALX Oncology	40	138.28 million	121.13 million	Optionable
CYPH Cypherpunk Technologies	40	107.76 million	102.74 million	Optionable
WHWK Whitehawk Therapeutics	21	57.01 million	28.56 million	N/A

CYPH, ALXO, WHWK, and ACIU Headlines

Recent News About These Companies

Whitehawk Therapeutics Inc WHWK

August 14 at 2:28 PM | morningstar.comM

TD Cowen Remains a Hold on Whitehawk Therapeutics (WHWK)

August 10, 2026 | theglobeandmail.com

Whitehawk Therapeutics (NASDAQ:WHWK) Upgraded by Wall Street Zen to Hold Rating

August 8, 2026 | americanbankingnews.com

Whitehawk Therapeutics (NASDAQ:WHWK) Rating Increased to Hold at Wall Street Zen

August 8, 2026 | marketbeat.com

Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS

August 6, 2026 | marketbeat.com

Whitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial Cancers

August 6, 2026 | tipranks.com

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 6, 2026 | prnewswire.com

Stempoint Capital LP Sells 519,438 Shares of Whitehawk Therapeutics, Inc. $WHWK

July 30, 2026 | marketbeat.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Rating of "Moderate Buy" from Analysts

July 25, 2026 | marketbeat.com

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

July 7, 2026 | businesswire.com

10 Hot Biotech Stocks Under $5 to Buy

June 10, 2026 | insidermonkey.com

Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?

June 10, 2026 | insidermonkey.com

Whitehawk Therapeutics Presents Realâ€‘World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

May 30, 2026 | gurufocus.com

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

May 30, 2026 | prnewswire.com

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

May 28, 2026 | prnewswire.com

WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise

May 21, 2026 | finance.yahoo.com

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

May 21, 2026 | prnewswire.com

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

May 20, 2026 | prnewswire.com

Whitehawk Therapeutics officer Ball sells $201k in stock

May 18, 2026 | investing.com

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

May 15, 2026 | prnewswire.com

Whitehawk’s First-in-Human PTK7 ADC Trial Moves Ahead: What Investors Should Know

May 14, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH, ALXO, WHWK, and ACIU Company Descriptions

AC Immune NASDAQ:ACIU

$2.49 -0.08 (-3.11%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.57 +0.08 (+3.21%)

As of 08/14/2026 07:58 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

ALX Oncology NASDAQ:ALXO

$1.96 +0.02 (+1.03%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.94 -0.02 (-0.97%)

As of 08/14/2026 07:34 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Cypherpunk Technologies NASDAQ:CYPH

$0.64 0.00 (-0.62%)

As of 08/14/2026 04:00 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Whitehawk Therapeutics NASDAQ:WHWK

$4.46 -0.22 (-4.70%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$4.28 -0.18 (-4.04%)

As of 08/14/2026 07:47 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYPH, ALXO, WHWK, and ACIU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYPH, ALXO, WHWK, and ACIU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYPH, ALXO, WHWK, and ACIU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH, ALXO, WHWK, and ACIU Company Descriptions

AC Immune NASDAQ:ACIU

ALX Oncology NASDAQ:ALXO

Cypherpunk Technologies NASDAQ:CYPH

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYPH, ALXO, WHWK, and ACIU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYPH, ALXO, WHWK, and ACIU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYPH, ALXO, WHWK, and ACIU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH, ALXO, WHWK, and ACIU Company Descriptions

AC Immune NASDAQ:ACIU

ALX Oncology NASDAQ:ALXO

Cypherpunk Technologies NASDAQ:CYPH

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools